Advertisement
Advertisement

NVCR

NVCR logo

NovoCure Limited Ordinary Shares

17.20
USD
Sponsored
0.00
0.00%
Jul 03, 09:30 UTC -4
Closed
exchange

After-Market

17.08

-0.12
-0.70%

NVCR Earnings Reports

Positive Surprise Ratio

NVCR beat 24 of 42 last estimates.

57%

Next Report

Date of Next Report
Jul 20, 2026
Estimate for Q2 26 (Revenue/ EPS)
$176.17M
/
-$0.33
Implied change from Q1 26 (Revenue/ EPS)
+1.22%
/
-46.77%
Implied change from Q2 25 (Revenue/ EPS)
+10.94%
/
-8.33%

NovoCure Limited Ordinary Shares earnings per share and revenue

On Apr 30, 2026, NVCR reported earnings of -0.62 USD per share (EPS) for Q1 26, missing the estimate of -0.52 USD, resulting in a -18.52% surprise. Revenue reached 174.06 million, compared to an expected 171.22 million, with a 1.65% difference. The market reacted with a +27.49% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.33 USD, with revenue projected to reach 176.17 million USD, implying an decrease of -46.77% EPS, and increase of 1.22% in Revenue from the last quarter.
FAQ
For Q1 2026, NovoCure Limited Ordinary Shares reported EPS of -$0.62, missing estimates by -18.52%, and revenue of $174.06M, 1.65% above expectations.
The stock price moved up 27.49%, changed from $11.93 before the earnings release to $15.21 the day after.
The next earning report is scheduled for Jul 20, 2026.
Based on -- analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.33 and revenue of $176.17M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement